351 related articles for article (PubMed ID: 29766022)
1. Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.
Fitzpatrick Z; Leborgne C; Barbon E; Masat E; Ronzitti G; van Wittenberghe L; Vignaud A; Collaud F; Charles S; Simon Sola M; Jouen F; Boyer O; Mingozzi F
Mol Ther Methods Clin Dev; 2018 Jun; 9():119-129. PubMed ID: 29766022
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
[TBL] [Abstract][Full Text] [Related]
3. Successful AAV8 readministration: Suppression of capsid-specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease.
Choi SJ; Yi JS; Lim JA; Tedder TF; Koeberl DD; Jeck W; Desai AK; Rosenberg A; Sun B; Kishnani PS
J Gene Med; 2023 Aug; 25(8):e3509. PubMed ID: 36994804
[TBL] [Abstract][Full Text] [Related]
4. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
[TBL] [Abstract][Full Text] [Related]
5. Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies.
Ito M; Takino N; Nomura T; Kan A; Muramatsu SI
Sci Rep; 2021 Apr; 11(1):9322. PubMed ID: 33927271
[TBL] [Abstract][Full Text] [Related]
6. Systemic and local immune responses to intraocular AAV vector administration in non-human primates.
Ail D; Ren D; Brazhnikova E; Nouvel-Jaillard C; Bertin S; Mirashrafi SB; Fisson S; Dalkara D
Mol Ther Methods Clin Dev; 2022 Mar; 24():306-316. PubMed ID: 35229004
[TBL] [Abstract][Full Text] [Related]
7. Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors.
Meliani A; Boisgerault F; Fitzpatrick Z; Marmier S; Leborgne C; Collaud F; Simon Sola M; Charles S; Ronzitti G; Vignaud A; van Wittenberghe L; Marolleau B; Jouen F; Tan S; Boyer O; Christophe O; Brisson AR; Maguire CA; Mingozzi F
Blood Adv; 2017 Oct; 1(23):2019-2031. PubMed ID: 29296848
[TBL] [Abstract][Full Text] [Related]
8. Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice.
Baatartsogt N; Kashiwakura Y; Hiramoto T; Hayakawa M; Kamoshita N; Ohmori T
J Gene Med; 2023 Aug; 25(8):e3505. PubMed ID: 36972408
[TBL] [Abstract][Full Text] [Related]
9. MSD-based assays facilitate a rapid and quantitative serostatus profiling for the presence of anti-AAV antibodies.
Haar J; Blazevic D; Strobel B; Kreuz S; Michelfelder S
Mol Ther Methods Clin Dev; 2022 Jun; 25():360-369. PubMed ID: 35573045
[TBL] [Abstract][Full Text] [Related]
10. Utility of microminipigs for evaluating liver-mediated gene expression in the presence of neutralizing antibody against vector capsid.
Watano R; Ohmori T; Hishikawa S; Sakata A; Mizukami H
Gene Ther; 2020 Sep; 27(9):427-434. PubMed ID: 32066928
[TBL] [Abstract][Full Text] [Related]
11. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive
Kruzik A; Koppensteiner H; Fetahagic D; Hartlieb B; Dorn S; Romeder-Finger S; Coulibaly S; Weber A; Hoellriegl W; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
[TBL] [Abstract][Full Text] [Related]
12. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
[TBL] [Abstract][Full Text] [Related]
13. Effects of Neutralizing Antibody Production on AAV-PHP.B-Mediated Transduction of the Mouse Central Nervous System.
Shinohara Y; Konno A; Nitta K; Matsuzaki Y; Yasui H; Suwa J; Hiromura K; Hirai H
Mol Neurobiol; 2019 Jun; 56(6):4203-4214. PubMed ID: 30291583
[TBL] [Abstract][Full Text] [Related]
14. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.
Mimuro J; Mizukami H; Hishikawa S; Ikemoto T; Ishiwata A; Sakata A; Ohmori T; Madoiwa S; Ono F; Ozawa K; Sakata Y
Mol Ther; 2013 Feb; 21(2):318-23. PubMed ID: 23247100
[TBL] [Abstract][Full Text] [Related]
15. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors.
Wang L; Calcedo R; Bell P; Lin J; Grant RL; Siegel DL; Wilson JM
Hum Gene Ther; 2011 Nov; 22(11):1389-401. PubMed ID: 21476868
[TBL] [Abstract][Full Text] [Related]
16. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
Janelidze S; Nordström U; Kügler S; Brundin P
J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
[TBL] [Abstract][Full Text] [Related]
17. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies.
Leborgne C; Barbon E; Alexander JM; Hanby H; Delignat S; Cohen DM; Collaud F; Muraleetharan S; Lupo D; Silverberg J; Huang K; van Wittengerghe L; Marolleau B; Miranda A; Fabiano A; Daventure V; Beck H; Anguela XM; Ronzitti G; Armour SM; Lacroix-Desmazes S; Mingozzi F
Nat Med; 2020 Jul; 26(7):1096-1101. PubMed ID: 32483358
[TBL] [Abstract][Full Text] [Related]
18. Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies.
Ros-Gañán I; Hommel M; Trigueros-Motos L; Tamarit B; Rodríguez-García E; Salas D; Pérez G; Douar A; Combal JP; Benichou B; Ferrer V; González-Aseguinolaza G
Clin Transl Immunology; 2022; 11(2):e1375. PubMed ID: 35228870
[TBL] [Abstract][Full Text] [Related]
19. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques.
Wang L; Calcedo R; Wang H; Bell P; Grant R; Vandenberghe LH; Sanmiguel J; Morizono H; Batshaw ML; Wilson JM
Mol Ther; 2010 Jan; 18(1):126-34. PubMed ID: 19888196
[TBL] [Abstract][Full Text] [Related]
20. Assessment of a passive immunity mouse model to quantitatively analyze the impact of neutralizing antibodies on adeno-associated virus-mediated gene transfer.
Sun L; Tu L; Gao G; Sun X; Duan J; Lu Y
J Immunol Methods; 2013 Jan; 387(1-2):114-20. PubMed ID: 23063691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
